A Randomized Phase III Trial of Memantine and Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
This randomized phase III trial compares memantine hydrochloride and whole-brain
radiation therapy with or without hippocampal avoidance in reducing neurocognitive decline in
patients with cancer that has spread from the primary site (place where it started) to the
brain. Whole brain radiation therapy (WBRT) is the most common treatment for brain metastasis.
Unfortunately, the majority of patients with brain metastases experience cognitive (such as
learning and memory) deterioration after WBRT. Memantine hydrochloride may enhance cognitive
function by binding to and inhibiting channels of receptors located in the central nervous
system. Radiation therapy uses high energy x-rays to kill tumour cells and shrink tumours.
Using radiation techniques, such as intensity modulated radiation therapy to avoid the
hippocampal region during WBRT, may reduce the radiation dose to the hippocampus and help
limit the radiation-induced cognitive decline. It is not yet known whether giving memantine
hydrochloride and WBRT with or without hippocampal avoidance works better in reducing
neurocognitive decline in patients with brain metastases.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society